Trials / Recruiting
RecruitingNCT07505069
Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Nanolattix Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
RT01-89Zr is a TF-targeting radiopharmaceutical diagnostic agent. This trial aims to evaluate the safety, biodistribution, dosimetry, and imaging characteristics of RT01-89Zr as a PET/CT tracer in patients with malignant solid tumors that highly express the TF target.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RT01-89Zr | Intravenous injection of RT01-89Zr with a dosage of 1-2 mCi |
Timeline
- Start date
- 2026-01-29
- Primary completion
- 2026-12-30
- Completion
- 2027-02-28
- First posted
- 2026-04-01
- Last updated
- 2026-04-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07505069. Inclusion in this directory is not an endorsement.